IVA vs XCH Comparison

Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.

XCHG Ltd engaged in designing, manufacturing and selling of Electric Vehicle (EV) chargers and EV charging solutions which include the DC fast chargers named the C6 series and the C7 series, the battery-integrated DC fast chargers which is Net Zero Series (NZS), as well as accompanying services. Its integrated solution combining proprietary charging technology, energy storage technology and accompanying services significantly improves EV charging efficiency and unlocks the value of energy storage and management. Its NZS solution enables fast charging at low power locations or vis-a-vis aged grid infrastructures (which typically are not compatible with fast charging equipment) with no site improvements or grid upgrades needed.